Acumen Pharmaceuticals Inc Sustainability Reports
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for Alzheimer's disease. Its lead investigational product candidate is sabirnetug, a humanized monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG0058YJ326
3 reports from 2021 to 2024
Company Profile
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for Alzheimer's disease. Its lead investigational product candidate is sabirnetug, a humanized monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers.
Reports
3 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
